Allergy Therapeutics Share Chat (AGY)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Allergy Therapeutics	LSE:AGY	London	Ordinary Share	GB00B02LCQ05	ORD 0.1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-0.75p	-2.86%	25.50p	25.00p	26.00p	26.25p	25.50p	26.25p	337,368	11:00:25

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	64.1	-2.0	-0.4	-	154.05

Allergy Therapeutics Share Discussion Threads

Showing 3526 to 3549 of 3550 messages

Chat Pages: 142 141 140 139 138 137 136 135 134 133 132 131 Older

Date	Subject	Author	Discuss
22/5/2018 18:57	Some good info in this interview. Must admit that I thought they would be in to the phase 3 program earlier than the Q3 2019 recruitment date stated. Huge opportunity though and the barriers to entry for others will be high so a little more patience required.	audigger	Read Full Thread Reply
22/5/2018 18:51	Today - IC Tip Update: Buy at 27p Megan Boxall The long await phase two clinical trial into Allergy Therapeutics’ (AGY) novel grass allergy vaccine has been successful. The trial managed to discover the appropriate dosage of the drug after a similar trial in 2015 failed to achieve any clinical significance. This latest update means Allergy can progress to its phase three study safe in the knowledge that patients are being given the appropriate dose. If the rest of Allergy’s product development goes according to plan, 2018 should be the last year that losses keep widening, according to Panmure Gordon. The grass vaccine, in particular, could be an enormous commercial success if it manages to pass its final trial thanks to the size of the allergy market, which is largely devoid of long-term treatments. IC View Even with the 9 per cent one-day share price hike which followed these results, Allergy’s share price is still down in the last 12 months. We don’t think that’s a fair reflection of the clinical progress that has been made in that time. Buy at 27p. Last IC View: Buy, 26p, 7 Mar 2018	gersemi	Read Full Thread Reply
22/5/2018 13:16	Afternoon, Short TV interview with both CEO Manuel Llobet and House broker Panmure Gordon's Healthcare Analyst Dr Mike Mitchell www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/	oshy92	Read Full Thread Reply
21/5/2018 09:42	Agreed, I trade ranges which means I almost always sell out too soon! Still, it's putting bread on the table and I'm long term on a couple of favourites. Must admit I like the story here, will be watching closely.	rathean	Read Full Thread Reply
21/5/2018 09:30	I use to regularly buy and sell these but some day soon it will take off so now I just buy the dips. That said I recently sold a number of other shares which I made money on but have absolutely flown since I sold! Such is investing. A profit is a profit! Will get the Ferrari when they hit 100p!	audigger	Read Full Thread Reply
21/5/2018 09:12	That's me out with a rather pleasant 10% gain. Very positive news though, will be back in when the price is right, gla.	rathean	Read Full Thread Reply
21/5/2018 08:41	You could upgrade to a Ferrari at this rate!	richsawko	Read Full Thread Reply
21/5/2018 08:28	Well there's some proof of concept for you! Looks like I timed my top-up well for once. I'm tempted to add more but spare cash is heading for a car purchase!	audigger	Read Full Thread Reply
21/5/2018 08:28	WOW 2.5M trade!	richsawko	Read Full Thread Reply
21/5/2018 08:00	Excellent announcement today looking positive for the future of this company	richsawko	Read Full Thread Reply
18/5/2018 09:20	Thanks gold digger, I like the story here and their revenue numbers despite a low pollen season last year are impressive. Took a nibble a few days ago.	rathean	Read Full Thread Reply
16/5/2018 14:33	We're still a way off having proof of concept from pivotal studies, hence a study in transgenic mice isn't going to lift the share price I've added another chunk today which means that this is approaching my largest single holding. I never look at technical analysis on early stage life science shares; they are somewhat meaningless. Good news from clinical trials and this will fly. Of course the converse is also true hence a moderately risky play. Management team seem impressive and they have a variety of technologies either one of which could be a commercial success.	audigger	Read Full Thread Reply
15/5/2018 09:48	So why the steep falling channel and no uplift on good clinical data?	rathean	Read Full Thread Reply
14/5/2018 16:57	Looks like this article has prompted today's rise: Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT®), in The Journal of Immunology Novel Findings Further Highlight the Effectiveness of MCT as Alternative to Alum and its Potential Advantage in Allergy-Specific Immunotherapy WORTHING, United Kingdom, 14 May 2018 - Allergy Therapeutics (AIM:AGY), a leading, fully-integrated commercial biotechnology company specialising in allergy vaccines, today announces that new data from a study investigating immune responses produced by microcrystalline tyrosine (MCT®)-based vaccines as compared with conventional aluminium hydroxide has been published online in The Journal of Immunology. The findings demonstrate that, based on its comparable strength and mechanism of Ag-specific IgG induction and induction of T cell responses, MCT® is a suitable and flexible alternative to aluminium hydroxide as an adjuvant in both allergen-specific immunotherapy and infectious disease applications. The study also demonstrated that MCT®-adjuvanted allergens caused fewer anaphylactic reactions compared with alum-adjuvanted allergens. "These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response. Additionally, the findings indicated a potentially favourable profile for the use of MCT over alum in allergy-specific vaccines," said Matthias Kramer, M.D., Allergy Therapeutics' International Medical Director and co-author of the paper. "We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines." This is the first study to report the mechanism of action by which MCT governs the immunologic response after exposure to an antigen and protection against anaphylaxis in an allergic model. The results illustrate upregulation of IgG antibody responses and a higher IgE:IgG ratio in MCT-based immunotherapy compared with Alum-based immunotherapy. A high IgE:IgG ratio has been reported to be a positive predictive marker for allergen immunotherapy in humans. Further evaluation in this study indicated that MCT facilitates robust adaptive T cell responses with associated IFN-γ (interferon gamma) and TNF-α (tumour necrosis factor alpha), which is in line with previous studies illustrating protective efficacy in influenza and malaria applications1, 2. Meanwhile, studies in a cancer (melanoma) model are underway. A link to publication is here: www.jimmunol.org/content/200/9/3151	audigger	Read Full Thread Reply
04/5/2018 15:26	New low for the year! :(	jpuff	Read Full Thread Reply
25/4/2018 19:09	"IF" the trials are seen as successful, it will be a real riot if they are not!	jimmyloser	Read Full Thread Reply
25/4/2018 18:43	Agreed, worked out my average purchase price of my accumulated holdings to be 12.7p, looking, like many, for 100p. I predict a riot when the trials are seen as successful DYOR/IMHO	aruntim	Read Full Thread Reply
12/4/2018 21:56	The potential upside remains significant IMO. Thus share has a pattern of making quicknrises then slowly drifting back over time. I guess ones ability to tolerate this depends on your entry point. Anyone who bought in above 30p will be feeling bad about nursing some paper losses. H2 2018 looks to be the start of a key period of news flow. I'm optimistic we may end the year around 40p so long as the US opportunity remains on track. My personal target is to sell these at 100p within the next 5-10 years.	audigger	Read Full Thread Reply
12/4/2018 10:51	I wouldn't let these go for love nor money! Others might have a confidence issue, I certainly don't! Withy Allergy they can RNS something positive at any time!	jimmyloser	Read Full Thread Reply
12/4/2018 10:35	Maybe if there's a general lack of confidence we should be holding something else! Too late for me now as I'm well under water here now :(	jpuff	Read Full Thread Reply
12/4/2018 09:51	Yes, it is just due to lack of confidence. They are prone to setbacks. Peeps are waiting for the outcome of the trials. As the company said themselves this is a transitional year! impo/dyor	jimmyloser	Read Full Thread Reply
12/4/2018 09:07	What is happening to these shares, now at a year low!	richsawko	Read Full Thread Reply
15/3/2018 12:22	The video from last week's Shares Mag presentation is now available: https://www.sharesmagazine.co.uk/video/nick-wykeman-fd-allergy-therapeutics-agy	timbo003	Read Full Thread Reply
08/3/2018 10:23	If they get a positive result on the two trials, this will (impo) fly past 40p in a re-rating. However if they don't???? Too cheap right now. dyor impo	jimmyloser	Read Full Thread Reply

Chat Pages: 142 141 140 139 138 137 136 135 134 133 132 131 Older

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.